.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
McKesson
AstraZeneca
Julphar
Cipla
US Department of Justice
Johnson and Johnson
Healthtrust
Cerilliant

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205390

« Back to Dashboard

NDA 205390 describes VECURONIUM BROMIDE, which is a drug marketed by Gland Pharma Ltd, Hospira, Mylan Labs Ltd, Sagent Pharms, Sun Pharma Global, Teva Pharms Usa, Watson Labs, and West-ward Pharms Int, and is included in ten NDAs. It is available from ten suppliers. Additional details are available on the VECURONIUM BROMIDE profile page.

The generic ingredient in VECURONIUM BROMIDE is vecuronium bromide. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.

Summary for 205390

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 205390

Medical Subject Heading (MeSH) Categories for 205390

Suppliers and Packaging for NDA: 205390

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 205390 ANDA Fresenius Kabi USA, LLC 63323-781 63323-781-10 10 VIAL in 1 CARTON (63323-781-10) > 10 mL in 1 VIAL
VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 205390 ANDA Fresenius Kabi USA, LLC 63323-782 63323-782-20 10 VIAL in 1 CARTON (63323-782-20) > 20 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength10MG/VIAL
Approval Date:May 26, 2016TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength20MG/VIAL
Approval Date:May 26, 2016TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Mallinckrodt
Colorcon
Teva
Express Scripts
Covington
Dow
Daiichi Sankyo
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot